AMD Insight Licenses ArcticDx's Age-related Macular Degeneration MDx Test | GenomeWeb

NEW YORK (GenomeWeb) – AMD Insight today announced it has exclusively licensed from ArcticDx the commercial rights in Canada for the Macula Risk PGx test.

Macula Risk PGx is a prognostic and pharmacogenetic DNA test for evaluating a patient's risk of progressing to advanced age-related macular degeneration and aids in choosing appropriate vitamin formulations for AMD based on the patient's genetic risk profile.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.